Evidence map›Paper›PMID 25964458›Full record

ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015

Vaccinology in the era of high-throughput biology.

Helder I Nakaya, Bali Pulendran

Abstract readReview
In one paragraph

Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. mSphere · 2021
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Maternal Immunization: Nature Meets Nurture.Frontiers in microbiology · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Helder I NakayaSchool of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil Emory Vaccine Center and Yerkes National Primate Research Center, Atlanta, GA 30329, USA Department of Pathology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Bali PulendranEmory Vaccine Center and Yerkes National Primate Research Center, Atlanta, GA 30329, USA Department of Pathology, Emory University School of Medicine, Atlanta, Georgia 30322, USA bpulend@emory.edu.

Funding

Yessinia autotransporters (Yaps): Structure, function, and host responseU54AI057157 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SEMPOWSKI, GREGORY D · 2003 to 2013
$91.4M
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7M
Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Immune Function and Biodefense in Immunocrompromised PopulationsN01AI50025 · NIAID · EMORY UNIVERSITY · 2007 to 2008
$8.1M
MODELING IMMUNITY FOR BIODEFENSEN01AI50019 · NIAID · DUKE UNIVERSITY · PI KEPLER, THOMAS B · 2007 to 2009
$5.1M
Understanding the Role of Mucosal Antigen Presenting Cells in Regulating Immune ResponseR37AI048638 · NIAID · STANFORD UNIVERSITY · PI PULENDRAN, BALI · 2009 to 2018
$4.0M
Polarizing T Cell Responses in vivo With Dendritic CellsR37DK057665 · NIDDK · STANFORD UNIVERSITY · PI PULENDRAN, BALI · 2010 to 2019
$3.9M
Emory R38 Research Training ProgramR38AI140299 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, ROUPHAEL, NADINE GEORGES · 2018 to 2021
$1.4M
IMMUNE FUNCTION AND BIODEFENSE IN CHILDREN. ELDERLY AND IMMUNOCOMPROMI-266050025N01AI050025 · NIAID · EMORY UNIVERSITY · PI LARSON, CHRIS · 2006 to 2006
–
NIAID NIH HHS N01 AI050019NIAID NIH HHS N01 AI050025NIAID NIH HHS N01 AI50019NIAID NIH HHS N01 AI50025NIAID NIH HHS R37 AI048638NIAID NIH HHS R38 AI140299NIAID NIH HHS U19 AI057266NIAID NIH HHS U19 AI090023NIAID NIH HHS U54 AI057157NIDDK NIH HHS R37 DK057665
6 · The paper itself

Abstract

Vaccination has been tremendously successful saving lives and preventing infections. However, the development of vaccines against global pandemics such as HIV, malaria and tuberculosis has been obstructed by several challenges. A major challenge is the lack of knowledge about the correlates and mechanisms of protective immunity. Recent advances in the application of systems biological approaches to analyse immune responses to vaccination in humans are beginning to yield new insights about mechanisms of vaccine immunity, and to define molecular signatures, induced rapidly after vaccination, that correlate with and predict vaccine induced immunity. Here, we review these advances and discuss the potential of this systems vaccinology approach in defining novel correlates of protection in clinical trials, and in infection-induced 'experimental challenge models' in humans.

Indexed as

AnimalsGenetic VariationHigh-Throughput Screening AssaysHumansImmune SystemSystems BiologyVaccinesVaccineshigh-throughput biologyimmunitysystems biologyvaccinology

Identifiers

PMID25964458
PMCPMC4527391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.